Details of the Drug

General Information of Drug (ID: DMEYNQA)

Drug Name
ALN-RSV01
Indication
Disease Entry ICD 11 Status REF
Respiratory infection CA07-CA4Z Phase 2 [1]
Respiratory syncytial virus infection 1C80 Phase 2 [2]
Drug Type
siRNA drug
Cross-matching ID
TTD ID
DNM9C4
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HRSV Nucleoprotein messenger RNA (HRSV N mRNA) TTWSF5D NCAP_HRSVA Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00658086) Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT00658086) Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV). U.S. National Institutes of Health.
3 Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 2008 Mar;77(3):225-31.